(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual meeting in Orlando, FL hosted a thought-provoking presentation by Dr. Pavlos Msaouel, MD, Ph.D. regarding the future of adjuvant therapy for high-risk non-metastatic renal cell carcinoma (RCC). Dr. Msaouel began his talk by presenting the seminal data from KEYNOTE-564 evaluating adjuvant pembrolizumab (KEYTRUDA ®) after nephrectomy in RCC.

X